Summary
The current state of knowledge about β-blockers in treating hypertension and their comparative pharmacology is reviewed. Some new developments in antihypertensive therapy, such as converting-enzyme inhibitors and calcium antagonistic drugs are discussed and their place vis-a-vis the β-blockers analysed.
Similar content being viewed by others
References
Barbarino, A. and De Marinis, L.: Calcium antagonists and hormone release. II. Effects of verapamil on basal, gonadotropin-releasing hormone and thyrotropin-releasing hormone-induced pituitary hormone release in normal subjects. Journal of Clinical Endocrinology and Metabolism 51: 749–754 (1980).
Bühler, F.R.; Burkhart, F.; Lutold, B.E.; Kung, M.; Marbet, G. and Pfisterer, M.: Antihypertensive beta-blocking action as related to renin and age: A pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. American Journal of Cardiology 35: 653–669 (1975).
Campbell, W.B.; Johnson, A.R.; Callahan, K.S. and Graham, R.M.: Anti-platelet activity of beta-adrenergic antagonists: Inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. Lancet 2: 1382–1384 (1981).
Day, J.L.; Metcalfe, J. and Simpson, C.N.: Adrenergic mechanisms in control of plasma lipid concentrations. British Medical Journal 284, 1145–1148 (1982).
Guazzi, M.; Olivari, M.T.; Polese, A.; Fiorentini, C.; Magrini, F. and Moruzzi, P.: Nifedipine, a new antihypertensive with rapid action. Clinical Pharmacology and Therapeutics 22: 528–532 (1977).
Jennings, G.L.; Esler, M.D. and Korner, P.I.: Effect of prolonged treatment on hemodynamics of essential hypertension before and after autonomic block. Lancet 2: 166–169 (1980).
Kaplan, N.M.: Clinical Hypertension (3rd ed.) pp. 98–192 (Williams and Wilkins, Baltimore 1982).
Lindemann, J.P.; Bailey, J.C. and Watanabe, A.M.: Potential biochemical mechanisms for regulation of the slow inward current: Theoretical basis for drug action. American Heart Journal 103: 746–755 (1982).
Lund-Johansen, P.: Hemodynamic consequences of long-term beta-blocker therapy: A 5-year follow-up study of atenolol. Journal of Cardiovascular Pharmacology 1: 487–495 (1979).
Meier, J.: Beta-adrenoceptor-blocking agents: Pharmacokinetic differences and their clinical implications illustrated on pindolol. Cardiology 64(Suppl. 1): 1–13 (1979).
Rubin, R.P.: Actions of calcium antagonists of secretory cells: in Weiss, G.B. (Ed.) New Perspectives on Calcium Antagonists, pp. 147–158 (American Physiology Society, Bethesda, Maryland 1981).
Seedat, Y.K.: Trial of atenolol and chlorthalidone for hypertension in black South Africans. British Medical Journal 281: 1241–1245 (1980).
Swales, J.D.; Bing, R.G.; Heagerty, A.; Pohl, J.E.F.; Russell, G.I. and Thurston, H.: Treatment of refractory hypertension. Lancet 1: 894–896 (1982).
Watson, R.D.S.; Stallard, T.J. and Littler, W.A.: Influence of once-daily administration of beta-adrenoceptor antagonists on arterial pressure and its variability. Lancet 1: 1210–1213 (1979).
Wilcox, R.G.: Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. British Medical Journal 2: 383–385 (1978).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaplan, N.M. The Present and Future Use of β-Blockers. Drugs 25 (Suppl 2), 1–4 (1983). https://doi.org/10.2165/00003495-198300252-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198300252-00002